ICP
TMO icon

Ironvine Capital Partners’s Thermo Fisher Scientific TMO Stock Holding History

Ironvine Capital Partners’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31M Sell
61,788
-2,297
-4% -$1.1M 2.89% 14
2026
Q1 		$31.5M Sell
64,085
-453
-0.7% -$246K 3.46% 14
2025
Q4 		$37.4M Sell
64,538
-21
-0% -$11.9K 3.74% 13
2025
Q3 		$31.3M Sell
64,559
-8,485
-12% -$3.95M 3.12% 13
2025
Q2 		$29.6M Sell
73,044
-3,933
-5% -$1.64M 3.07% 14
2025
Q1 		$38.3M Buy
76,977
+4,188
+6% +$2.27M 4.16% 11
2024
Q4 		$37.9M Sell
72,789
-4,916
-6% -$2.7M 4.06% 11
2024
Q3 		$48.1M Buy
77,705
+205
+0.3% +$121K 5.16% 7
2024
Q2 		$42.9M Sell
77,500
-29
-0% -$16.6K 4.69% 6
2024
Q1 		$45.1M Buy
77,529
+285
+0.4% +$160K 4.94% 5
2023
Q4 		$41M Sell
77,244
-3,156
-4% -$1.53M 4.92% 5
2023
Q3 		$40.7M Buy
80,400
+830
+1% +$442K 5.22% 4
2023
Q2 		$41.5M Sell
79,570
-726
-0.9% -$392K 5.04% 6
2023
Q1 		$46.3M Buy
80,296
+225
+0.3% +$127K 5.84% 2
2022
Q4 		$44.1M Buy
80,071
+4,019
+5% +$2.13M 5.71% 2
2022
Q3 		$38.6M Buy
76,052
+3,088
+4% +$1.73M 5.18% 3
2022
Q2 		$39.6M Buy
72,964
+1,124
+2% +$619K 4.87% 4
2022
Q1 		$42.4M Buy
71,840
+1,661
+2% +$954K 4.58% 5
2021
Q4 		$46.8M Sell
70,179
-10,096
-13% -$6.3M 4.8% 4
2021
Q3 		$45.9M Buy
80,275
+2,574
+3% +$1.41M 4.87% 4
2021
Q2 		$39.2M Buy
77,701
+23,255
+43% +$11M 4.29% 7
2021
Q1 		$24.8M Buy
54,446
+792
+1% +$378K 2.89% 14
2020
Q4 		$25M Sell
53,654
-7,160
-12% -$3.36M 3.12% 12
2020
Q3 		$26.9M Buy
60,814
+18
+0% +$7.44K 3.36% 11
2020
Q2 		$22M Buy
60,796
+44
+0.1% +$14.7K 2.91% 14
2020
Q1 		$17.2M Buy
60,752
+8,871
+17% +$2.8M 2.69% 14
2019
Q4 		$16.9M Buy
51,881
+859
+2% +$260K 2.03% 17
2019
Q3 		$14.5M Buy
51,022
+4,950
+11% +$1.42M 2.12% 19
2019
Q2 		$13.3M Buy
46,072
+2,854
+7% +$786K 2.17% 22
2019
Q1 		$11.8M Buy
+43,218
New +$10.8M 2.23% 17

Other funds holding TMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Ironvine Capital Partners's TMO Position: Q2 2026 in Review

Ironvine Capital Partners reduced its Thermo Fisher Scientific (TMO) stake by 3.6% in Q2 2026, selling an estimated $1.1M and leaving 61,788 shares worth $31M. The position accounts for 2.89% of the portfolio, ranked #14.

Ironvine Capital Partners first reported a position in TMO in Q1 2019 and has held it in 30 quarters since. The position peaked at $48.1M in Q3 2024. 2,623 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Ironvine Capital Partners held 61,788 shares of Thermo Fisher Scientific worth $31M as of Q2 2026.
  • Ironvine Capital Partners sold 2,297 Thermo Fisher Scientific shares in Q2 2026, an estimated $1.1M.
  • Thermo Fisher Scientific made up 2.89% of Ironvine Capital Partners's portfolio in Q2 2026, its #14 holding.
  • Ironvine Capital Partners first reported a position in Thermo Fisher Scientific in Q1 2019 and has held it in 30 quarters since.
  • Ironvine Capital Partners's Thermo Fisher Scientific position peaked at $48.1M in Q3 2024.
  • 2,623 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Ironvine Capital Partners's 13F filing for Q2 2026, filed 10 Aug 2026.